The estimated Net Worth of Francis Duhay is at least $137 Thousand dollars as of 17 May 2021. Francis Duhay owns over 9,492 units of Hancock Jaffe Laboratories Inc stock worth over $136,601 and over the last 6 years Francis sold HJLI stock worth over $0.
Francis has made over 1 trades of the Hancock Jaffe Laboratories Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Francis bought 9,492 units of HJLI stock worth $50,592 on 17 May 2021.
The largest trade Francis's ever made was buying 9,492 units of Hancock Jaffe Laboratories Inc stock on 17 May 2021 worth over $50,592. On average, Francis trades about 2,373 units every 0 days since 2018. As of 17 May 2021 Francis still owns at least 13,160 units of Hancock Jaffe Laboratories Inc stock.
You can see the complete history of Francis Duhay stock trades at the bottom of the page.
Francis's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman, and Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include: